Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLIA Guidance Draws Industry Criticism On User Comparability Studies

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers seeking waived status for diagnostic tests should be able to choose a statistically appropriate sample for user comparability tests, according to comments submitted by industry on FDA's March 1 draft guidance on criteria for CLIA waiver applications.

You may also be interested in...



HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'

Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.

HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'

Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.

CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies

Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel